Animal models for neural diseases.
"Animal Models of Neural Disease" was the focus of General Session 5 at a 2010 scientific symposium that was sponsored jointly by the Society of Toxicologic Pathology (STP) and the International Federation of Societies of Toxicologic Pathologists (IFSTP). The objective was to consider issues that dictate the choice of animal models for neuropathology-based studies used to investigate neurological diseases and novel therapeutic agents to treat them. In some cases, no animal model exists that recapitulates the attributes of the human disease (e.g., fibromyalgia syndrome). Alternatively, numerous animal models are available for other conditions, so an essential consideration is selecting the most appropriate experimental system (e.g., Alzheimer's disease). New technologies (e.g., genetically engineered rodent models) promise the opportunity to generate suitable animal models for syndromes that currently lack any in vivo animal model, while in vitro models offer the opportunity to evaluate xenobiotic effects in specific neural cell populations. The complex nature of neurological disease requires regular reassessment of available and potential options to ensure that animal-derived data sets support translational medicine efforts to improve public health.
Pfizer Global Research, Groton, CT 06340, USA. Thomas.P.Brown@pfizer.com
Gary W
GW
Jay
Ronald B
RB
Demattos
Edward J
EJ
Weinstein
Martin A
MA
Philbert
Ingrid D
ID
Pardo
Tom P
TP
Brown
D000544:Alzheimer Disease / Q000628:therapy; D000818:Animals; D030801:Animals, Genetically Modified; D003226:Congresses as Topic; D004195:Disease Models, Animal; D005356:Fibromyalgia / Q000473:pathology; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced / Q000473:pathology*; D020258:Neurotoxicity Syndromes / Q000473:pathology* / Q000628:therapy; D009498:Neurotoxins; D012958:Societies, Scientific
D009498:Neurotoxins